A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 32, Issue 3, 2013, Pages 387-397

  Kohno, S ^a   Izumikawa, K ^a   Yoshida, M ^b   Takesue, Y ^c   Oka, S ^d   Kamei, K ^e   Miyazaki, Y ^f   Yoshinari, T ^g   Kartsonis, N A ^h   Niki, Y ⁱ  

^a NAGASAKI UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^g Merck Sharp Dohm Res Labs Japan   (Japan)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; MICAFUNGIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOMA; BLOOD PRESSURE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; ERYTHEMA; ESOPHAGUS CANDIDIASIS; EYE DISEASE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; HYPESTHESIA; INFECTION; INFESTATION; INJECTION SITE REACTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; JAPANESE; LEUKOCYTE COUNT; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PHLEBITIS; POPULATION RESEARCH; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTE COUNT; TREATMENT RESPONSE; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; DOUBLE-BLIND METHOD; DRUG TOXICITY; ECHINOCANDINS; FEMALE; HUMANS; JAPAN; LIPOPEPTIDES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874109154     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1754-z     Document Type: Article

References (18)

1. Kriengkauykiat J, Ito JI, Dadwal SS (2011) Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol 3:175-191
2. Kume H, Yamazaki T, Togano T, Abe M, Tanuma H, Kawana S et al (2011) Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in annual of pathological autopsy cases in Japan. Med Mycol J 52:117-127
3. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ et al (2002) A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113:294-299
4. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029
5. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563-1571
6. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402
7. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ et al (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883-893
8. Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR et al (2010) Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 32:637-648
9. ICH Harmonized Tripartite Guideline (1994) Clinical safety data management: definitions and standards for expedited reporting. Recommended for Adoption at Step 4 of the ICH Process on 27 October 1994 by the ICH Steering Committee. Available online at: http://www.pmda.go.jp/ich/e/e2a-95-3-20e.pdf
10. DCTD, NCI, NIH, DHHS (2003) Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. Available online at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf. Accessed 9 August 2006
11. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529-1535
12. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturveli V et al (2008) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard - second edition (M38-A2). Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, vol. 28, no. 16
13. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturveli V et al (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard - third edition (M27-A3). Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, vol. 28, no. 14
14. Hanadate T, Wakasugi M, Sogabe K, Kobayashi T, Horita H, Kawamura I et al (2011) Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report. J Infect Chemother 17:622-632
15. The Japanese Mycology Study Group (ed) (2007) Guidelines for management of deep-seated mycoses 2007. Kyowa Kikaku, Tokyo
16. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN (2011) Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 69:45-50
17. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M et al (2004) A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39:842-849
18. Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R et al (2010) Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 61:410-418